Table of Contents Author Guidelines Submit a Manuscript
Pathology Research International
Volume 2013 (2013), Article ID 920972, 12 pages
http://dx.doi.org/10.1155/2013/920972
Research Article

Immunoreactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Primary Lymphoid Tumors and Lymph Node Metastasis

1Laboratory of Recognition and Biological Activity Assays, Department of Quality Control, Center of Molecular Immunology, P.O. Box 16040, 216 Street and 15 Avenue Atabey, Playa, 11600 Havana, Cuba
2Department of Cell Biology and Tissues Banking, National Institute of Oncology and Radiobiology, 29 and F Street Vedado, Plaza de la Revolución, 10400 Havana, Cuba
3Department of Pathology, Manuel Fajardo General Hospital, Zapata and D Street Vedado, Plaza de la Revolución, 10400 Havana, Cuba
4Clinical Trials Unit, National Institute of Oncology and Radiobiology, 29 and F Street Vedado, Plaza de la Revolución, 10400 Havana, Cuba
5Department of Pathology, National Institute of Oncology and Radiobiology, 29 and F Street Vedado, Plaza de la Revolución, 10400 Havana, Cuba
6Research and Development Direction, Center of Molecular Immunology, P.O. Box 16040, 216 Street and 15 Avenue Atabey, Playa, 11600 Havana, Cuba

Received 31 July 2013; Revised 30 September 2013; Accepted 10 October 2013

Academic Editor: Shahid Pervez

Copyright © 2013 Rancés Blanco et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. M. El-Sayed, M. H. El-Borai, A. A. Bahnassy, and S. M. S. El-Gerzawi, “Flow cytometric immunophenotyping (FCI) of lymphoma: correlation with histopathology and immunohistochemistry,” Diagnostic Pathology, vol. 3, no. 1, article 43, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Berthold and M. Ghielmini, “Treatment of malignant lymphoma,” Swiss Medical Weekly, vol. 134, no. 33-34, pp. 472–480, 2004. View at Google Scholar · View at Scopus
  3. J. Weng, S. Rawal, F. Chu et al., “TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas,” Blood, vol. 120, no. 8, pp. 1613–1623, 2012. View at Publisher · View at Google Scholar
  4. E. L. Walk and S. A. Weed, “Recently identified biomarkers that promote lymph node metastasis in head and neck squamous cell carcinoma,” Cancers, vol. 3, no. 1, pp. 747–772, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. G. DiSibio and S. W. French, “Metastatic patterns of cancers: results from a large autopsy study,” Archives of Pathology and Laboratory Medicine, vol. 132, no. 6, pp. 931–939, 2008. View at Google Scholar · View at Scopus
  6. T. Yamashita, R. Wada, T. Sasaki et al., “A vital role for glycosphingolipid synthesis during development and differentiation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 16, pp. 9142–9147, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. A. M. Vazquez, M. Alfonso, B. Lanne et al., “Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acid-containing gangliosides that also recognizes sulfated glycolipids,” Hybridoma, vol. 14, no. 6, pp. 551–556, 1995. View at Google Scholar · View at Scopus
  8. A. Carr, A. Mullet, Z. Mazorra et al., “A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors,” Hybridoma, vol. 19, no. 3, pp. 241–247, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Osorio, E. Gracia, E. Rodríguez et al., “Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a phase Ib/IIa study,” Cancer Biology and Therapy, vol. 7, no. 4, pp. 488–495, 2008. View at Google Scholar · View at Scopus
  10. R. Blanco, E. Rengifo, M. Cedeño, C. E. Rengifo, D. F. Alonso, and A. Carr, “Immunoreactivity of the 14F7 Mab raised against N-Glycolyl GM3 ganglioside in epithelial malignant tumors from digestive system,” ISRN Gastroenterology, vol. 2011, Article ID 645641, 8 pages, 2011. View at Publisher · View at Google Scholar
  11. H. van Cruijsen, M. Ruiz, P. van der Valk, T. D. de Gruijl, and G. Giaccone, “Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer,” BMC Cancer, vol. 9, article 180, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. A. M. Scursoni, L. Galluzzo, S. Camarero et al., “Detection of N-glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: an attractive vaccine target for aggressive pediatric cancer,” Clinical and Developmental Immunology, vol. 2011, Article ID 245181, 6 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. A. M. Scursoni, L. Galluzzo, S. Camarero et al., “Detection and characterization of N-glycolyated gangliosides in Wilms tumor by immunohistochemistry,” Pediatric and Developmental Pathology, vol. 13, no. 1, pp. 18–23, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Blanco, E. Rengifo, C. E. Rengifo, M. Cedeño, M. Frómeta, and A. Carr, “Immunohistochemical reactivity of the 14F7 monoclonal antibody raised against N-glycolyl GM3 ganglioside in some benign and malignant skin neoplasms,” ISRN Dermatology, vol. 2011, Article ID 848909, 8 pages, 2011. View at Publisher · View at Google Scholar
  15. R. Blanco, M. Cedeño, X. Escobar et al., “Immunorecognition of the 14F7 Mab raised against N-Glycolyl GM3 ganglioside in some normal and malignant tissues from genitourinary system,” ISRN Pathology, vol. 2011, Article ID 953803, 10 pages, 2011. View at Publisher · View at Google Scholar
  16. R. Blanco, C. E. Rengifo, M. Cedeño, M. Frómeta, E. Rengifo, and A. Carr, “Immunoreactivity of the 14F7 MAb (raised against N-glycolyl GM3 ganglioside) as a positive prognostic factor in non-small cell lung cancer,” Pathology Research International, vol. 2012, Article ID 235418, 12 pages, 2012. View at Publisher · View at Google Scholar
  17. R. Blanco, Y. Quintana, D. Blanco et al., “Tissue reactivity of the 14F7 MAb raised against N-glycolyl GM3 ganglioside in tumors of neuroectodermal, mesodermal and epithelial origin,” Journal of Biomarkers Journal of Biomarkers, vol. 2013, Article ID 602417, 9 pages, 2013. View at Publisher · View at Google Scholar
  18. Y. Zhong, Y. Wu, C. Li et al., “N-Glycolyl GM3 ganglioside immunoexpression in oral mucosal melanomas of Chinese,” Oral Diseases, vol. 18, no. 8, pp. 741–747, 2012. View at Publisher · View at Google Scholar
  19. A. M. Vázquez, A. Pérez, A. M. Hernández et al., “Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody,” Hybridoma, vol. 17, no. 6, pp. 527–534, 1998. View at Google Scholar · View at Scopus
  20. L. Roque-Navarro, K. Chakrabandhu, J. de León et al., “Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity,” Molecular Cancer Therapeutics, vol. 7, no. 7, pp. 2033–2041, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Schwarz and A. H. Futerman, “Determination of the localization of gangliosides using anti-ganglioside antibodies: comparison of fixation methods,” Journal of Histochemistry and Cytochemistry, vol. 45, no. 4, pp. 611–618, 1997. View at Google Scholar · View at Scopus
  22. D. F. Alonso, “A novel hydrophobized GM3 ganglioside/Neisseria meningitidis outer-membrane-protein complex vaccine induces tumor protection in B16 murine melanoma,” International Journal of Oncology, vol. 15, no. 1, pp. 59–66, 1999. View at Google Scholar · View at Scopus
  23. N. Hayashi, H. Chiba, K. Kuronuma et al., “Detection of N-glycolyated gangliosides in non-small-cell lung cancer using GMR8 monoclonal antibody,” Cancer Science, vol. 104, no. 1, pp. 43–47, 2013. View at Publisher · View at Google Scholar
  24. N. Anh-Tuan, J. Pick, A. Mod, and S. R. Hollan, “Gangliosides in acute myeloid leukaemia (AML) and non-Hodgkin's lymphoma (NHL),” European Journal of Cancer and Clinical Oncology, vol. 22, no. 8, pp. 1003–1007, 1986. View at Google Scholar · View at Scopus
  25. K. P. O'Boyle, K. Freeman, A. Kalisiak, A. Agregado, and D. A. Scheinberg, “Patterns of ganglioside expression in B cell neoplasms,” Leukemia and Lymphoma, vol. 21, no. 3-4, pp. 255–266, 1996. View at Google Scholar · View at Scopus
  26. H. Higashi, Y. Nishi, Y. Fukui et al., “Tumor-associated expression of glycosphingolipid Hanganutziu-Deicher antigen in human cancers,” Gann, vol. 75, no. 11, pp. 1025–1029, 1984. View at Google Scholar · View at Scopus
  27. Y. N. Malykh, R. Schauer, and L. Shaw, “N-glycolylneuraminic acid in human tumours,” Biochimie, vol. 83, no. 7, pp. 623–634, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Tangvoranuntakul, P. Gagneux, S. Diaz et al., “Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 21, pp. 12045–12050, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Bardor, D. H. Nguyen, S. Diaz, and A. Varki, “Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells,” The Journal of Biological Chemistry, vol. 280, no. 6, pp. 4228–4237, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Nishimaki, K. Kano, and F. Milgrom, “Hanganutziu-Deicher antigen and antibody in pathologic sera and tissues,” Journal of Immunology, vol. 122, no. 6, pp. 2314–2318, 1979. View at Google Scholar · View at Scopus
  31. H. Higashi, M. Naiki, S. Matuo, and K. Okouchi, “Antigen of “serum sickness” type of heterophile antibodies in human sera: identification as gangliosides with N-glycolylneuraminic acid,” Biochemical and Biophysical Research Communications, vol. 79, no. 2, pp. 388–395, 1977. View at Google Scholar · View at Scopus
  32. D. H. Nguyen, P. Tangvoranuntakul, and A. Varki, “Effects of natural human antibodies against a nonhuman sialic acid that metabolically incorporates into activated and malignant immune cells,” Journal of Immunology, vol. 175, no. 1, pp. 228–236, 2005. View at Google Scholar · View at Scopus
  33. T. Kawai, A. Kato, H. Higashi, S. Kato, and M. Naiki, “Quantitative determination of N-glycolylneuraminic acid expression in human cancerous tissues and avian lymphoma cell lines as a tumor-associated sialic acid by gas chromatography-mass spectrometry,” Cancer Research, vol. 51, no. 4, pp. 1242–1246, 1991. View at Google Scholar · View at Scopus
  34. E. G. Kanduma, J. C. Mukuria, and O. W. Mwanda, “Serum total sialic acid and Hanganutziu-Deicher antibody in normals and in cancer patients,” East African Medical Journal, vol. 84, no. 5, pp. 207–214, 2007. View at Google Scholar · View at Scopus
  35. A. Carr, E. Rodríguez, M. D. C. Arango et al., “Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine,” Journal of Clinical Oncology, vol. 21, no. 6, pp. 1015–1021, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Osorio, E. Gracia, E. Reigosa et al., “Effect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma,” Cancer Management and Research, vol. 4, pp. 341–345, 2012. View at Publisher · View at Google Scholar
  37. K. Pérez, M. Osorio, J. Hernández, A. Carr, and L. E. Fernández, “NGcGM3/VSSP vaccine as treatment for melanoma patients,” Human vaccines and immunotherapeutics, vol. 9, no. 6, pp. 1237–1240, 2013. View at Publisher · View at Google Scholar
  38. G. Lauc and M. Heffer-Lauc, “Shedding and uptake of gangliosides and glycosylphosphatidylinositol-anchored proteins,” Biochimica et Biophysica Acta, vol. 1760, no. 4, pp. 584–602, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. R. McKallip, R. Li, and S. Ladisch, “Tumor gangliosides inhibit the tumor-specific immune response,” Journal of Immunology, vol. 163, no. 7, pp. 3718–3726, 1999. View at Google Scholar · View at Scopus
  40. S. Birklé, G. Zeng, L. Gao, R. K. Yu, and J. Aubry, “Role of tumor-associated gangliosides in cancer progression,” Biochimie, vol. 85, no. 3-4, pp. 455–463, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. J. de León, A. Fernández, M. Clavell et al., “Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4+CD25- effector and naturally occurring CD4+CD25+ regulatory T cells function,” International Immunology, vol. 20, no. 4, pp. 591–600, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. A. J. Cochran, R. Huang, J. Lee, E. Itakura, S. P. L. Leong, and R. Essner, “Tumour-induced immune modulation of sentinel lymph nodes,” Nature Reviews Immunology, vol. 6, no. 9, pp. 659–670, 2006. View at Google Scholar
  43. A. Carr, C. Mesa, M. D. C. Arango, A. M. Vázquez, and L. E. Fernández, “In vivo and in vitro anti-tumor effect of 14F7 monoclonal antibody,” Hybridoma and Hybridomics, vol. 21, no. 6, pp. 463–468, 2002. View at Google Scholar · View at Scopus
  44. A. Zhiqiang, “Antibody Therapeutics—a mini review,” Trends in Bio/Pharmaceutical Industry, vol. 2, pp. 24–29, 2008. View at Google Scholar
  45. Y. Fernández-Marrero, L. Roque-Navarro, T. Hernández et al., “A cytotoxic humanized anti-ganglioside antibody produced in a murine cell line defective of N-glycolylated-glycoconjugates,” Immunobiology, vol. 16, no. 12, pp. 1239–12347, 2001. View at Publisher · View at Google Scholar